The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArecor Therape Regulatory News (AREC)

Share Price Information for Arecor Therape (AREC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.50
Bid: 135.00
Ask: 140.00
Change: 0.00 (0.00%)
Spread: 5.00 (3.704%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 137.50
AREC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Feb 2023 16:44

RNS Number : 0448R
Arecor Therapeutics PLC
24 February 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Arecor Therapeutics Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Calculus Capital Limited

City and country of registered office (if applicable)

12 Conduit Street, London, W1S 2XH, UK

4. Full name of shareholder(s) (if different from 3.) v

Name

Investec Wealth and Investment

City and country of registered office (if applicable)

30 Gresham Street, London, EC2V 7QN, UK

5. Date on which the threshold was crossed or reached vi:

04/09/2022

6. Date on which issuer notified (DD/MM/YYYY):

22/02/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

7.96

7.96

2,425,364

Position of previous notification (if

applicable)

8.71

8.71

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BMWLM973

2,425,364

7.96

SUBTOTAL 8. A

2,425,364

7.96

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

n/a

The number and % of voting rights held

n/a

The date until which the voting rights will be held

n/a

11. Additional information xvi

 

Place of completion

London

Date of completion

22/02/2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUSSNROOUUUAR
Date   Source Headline
3rd May 20244:44 pmRNSPublication of Full Year Financial Results delayed
29th Apr 20247:00 amRNSNotice of results
23rd Apr 20247:00 amRNSBOARD CHANGE
12th Mar 20248:58 amRNSArecor and TRx Biosciences research collaboration
12th Mar 20247:00 amRNSArecor and TRx Biosciences research collaboration
29th Feb 20247:00 amRNSArecor announces launch of Ogluo® in Netherlands
1st Feb 20247:00 amRNSYear End Trading Update
23rd Jan 20244:58 pmRNSArecor announces update on INBRX-101
18th Jan 20247:00 amRNSArecor granted key European patent
8th Jan 20247:00 amRNSExpansion of specialty hospital collaboration
3rd Jan 20247:00 amRNSAppointment of SVP for Tetris Pharma Ltd
4th Dec 20237:00 amRNSAgreement with global medical products company
29th Nov 20237:00 amRNSArecor Continues Collaboration with Lilly
17th Nov 20237:00 amRNSProduct with Arestat technology launched in Europe
2nd Nov 20237:00 amRNSInhibrx milestone triggers payment to Arecor
1st Nov 20233:31 pmRNSExercise of rollover options & Total Voting Rights
2nd Oct 20237:00 amRNSProgress of Phase I clinical study of AT278
15th Sep 20237:00 amRNSArecor on Investor Meet Company Platform
14th Sep 20237:00 amRNSInterim Results for six months ended 30 June 2023
7th Sep 20237:00 amRNSArecor: positive Hikma FDA pre-IND meeting
4th Sep 20237:00 amRNSTETRIS PHARMA ANNOUNCES AGREEMENT WITH GOODLIFE
17th Aug 20237:00 amRNSCollaboration With Top 10 Global Pharma
10th Aug 20237:00 amRNSNotice of Interim Results
20th Jul 20237:00 amRNSArecor Business Update
5th Jul 20237:00 amRNSAdditional Agreement with Leading Biopharma
27th Jun 20237:00 amRNSArecor granted key patents in Europe and China
26th Jun 20237:00 amRNSArecor presents positive data for AT247 at ADA
9th Jun 20233:35 pmRNSExercise of rollover options & Total Voting Rights
9th Jun 202312:43 pmRNSResult of AGM
9th Jun 20237:00 amRNSAGM Statement
24th May 20237:00 amRNSDirector/PDMR Shareholding
15th May 20237:00 amRNSTETRIS PHARMA LAUNCHES OGLUO® IN DENMARK & NORWAY
4th May 20234:00 pmRNSARECOR 2022 ANNUAL REPORT AND NOTICE OF AGM
26th Apr 20237:00 amRNSArecor Granted Key U.S Patent
21st Apr 20237:00 amRNSArecor on Investor Meet Company Platform
20th Apr 20237:00 amRNSUnaudited Preliminary Results for 2022
5th Apr 20237:00 amRNSArecor Appoints Chief Business Officer
22nd Mar 20237:00 amRNSFIRST PATIENT DOSED IN AT278 CLINICAL TRIAL
13th Mar 20234:35 pmRNSPrice Monitoring Extension
13th Mar 20232:05 pmRNSSecond Price Monitoring Extn
13th Mar 20232:00 pmRNSPrice Monitoring Extension
13th Mar 202311:05 amRNSSecond Price Monitoring Extn
13th Mar 202311:00 amRNSPrice Monitoring Extension
13th Mar 20239:05 amRNSSecond Price Monitoring Extn
13th Mar 20239:00 amRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSARECOR TO PRESENT SHARESOC WEBINAR
24th Feb 20234:44 pmRNSHolding(s) in Company
24th Feb 20237:00 amRNSNotice of Results
16th Feb 20237:00 amRNSArecor Granted Patents in India and the US
14th Feb 20237:01 amRNSARECOR STRENGTHENS COLLABORATION WITH PARTNER

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.